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Abstract
Background: Fibroblast growth factor 2, a well-characterized heparin-binding growth factor, is involved in many
biological processes like embryogenesis, cell proliferation and angiogenesis. However, this growth factor is very
unstable and shows rapid degradation in aqueous solution. Beside the well-known stabilization of FGF2 by heparin
or heparan sulphate, the recently discovered binding to ATP also shows a stabilizing and protective effect on this
growth factor.
Results: Here we determined the dissociation constant of ATP on FGF2 by equilibrium microdialysis (KD: 59.8 μM)
and analyzed the impact of this binding on secondary structure by CD-spectroscopy. ATP-binding to FGF2
significantly changed the secondary structure of this growth factor with a shift to random coil structure elements.
We also analyzed the influence of this binding on the stability of FGF2 in aqueous solution over a period of 2 h.
While the amount of untreated FGF2 is reduced drastically over this period of time, ATP-binding reduces the
degradation considerably.
Conclusions: Taken together, our data suggest an important role of ATP in FGF2-stabilization beside the well
known-role of heparin and heparan sulphate.
Background
Some groups of protein families are known to bind
ATP, for example kinases and ABC transporters. Both
protein families possess a conserved ATP-binding
domain called P-loop (formerly Walker motif A: GXXG
(X)XGKT(X); [1,2]. However, ATP-binding which is not
based on a specific ATP-binding domain, is described
for many other proteins like lactoferrin [3], bovine
serum albumin [4] or gelsolin [5]. Recently, the interac-
tion of ATP with growth factors was discovered [6]. The
physiological role of this ATP-binding to growth factors
remained unclear. However, binding of ATP to NGF
and FGF2 seems to be essential for their neuroprotectiv-
ity as demonstrated with hippocampal neuronal cells
[7,8]. The heparin binding domain (HBD) of both
growth factors is important for ATP-binding [7,9]
although crystallographic data of the growth factor/
ATP-complexes are not yet available.
Complex formation of ATP with NGF and FGF2 is
probably based on ionic interaction of the negatively
charged phosphate residues of ATP with positively
charged arginine and lysine residues located in the HBD
of NGF and FGF2, respectively. This is similar to the
interaction of sulphate residues of heparin or heparan
sulphate-proteoglycans (HSPGs) with heparin-binding
growth factors like fibroblast growth factors, VEGF,
NGF or PDGF [10,11]. Additionally, binding of ATP to
FGF2 stabilizes the growth factor and protects it from
thermal degradation and proteolytic cleavage with tryp-
sin, neutrophil elastase (NE) or plasmin [12].
In this paper we determined the dissociation constant
(KD) of ATP-binding to FGF2 and analyzed the impact
on the conformation of the protein. Furthermore, we
investigated the consequence of this nucleotide binding
on FGF2 stability in aqueous solution to get a more
detailed insight into this probably important protein-
ligand interaction.
Correspondence: rosek@uni-muenster.de
Institut für Pharmazeutische und Medizinische Chemie, Westfälische
Wilhelms-Universität Münster, Hittorfstr. 58-62, 48149 Münster, Germany
Rose BMC Biochemistry 2011, 12:14
http://www.biomedcentral.com/1471-2091/12/14
© 2011 Rose; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.Methods
Equilibrium-microdialysis
Rapid equilibrium dialysis inserts (RED device inserts,
Pierce, IL, USA) were used along with Teflon Base Plate
(Pierce, Il, USA) for equilibrium dialysis experiments.
These inserts contain two 750-μL chambers separated
by 8,000 Da molecular mass cut-off. One chamber was
filled with FGF2 (10 μM) in 25 mM Tris-HCl, pH 7.5
(550 μL), and the other with various concentrations of
ATP in 25 mM Tris-HCl, pH 7.5. The dialysis inserts
were rotated at room temperature with a speed of
250 rpm and equilibrium was reached within 4 h as
monitored by counting an aliquot from both sides of
the membrane at different time points during dialysis.
After 4 h, 50 μL aliquots of the dialysis chambers were
removed and kept on ice. ATP was determined immedi-
ately. The experiments were performed in triplicate.
CD measurement
Far-UV spectra (195-250 nm) were recorded at FGF2
concentration of 25 μM with a Jasco-J600 spectropolari-
meter at room temperature in a 0.1-cm cell with 4 accu-
mulations. Measurements were performed in 25 mM
Tris-HCl (pH 7.5), and all spectra were corrected for
buffer and nucleotide background. The results are
expressed as ellipticities related to the mean residue
weight of amino acids as described before [7].
Chemical cross-linking experiments
For cross-linking studies, FGF2 (5 μM) in Tris-HCl (pH
7.5) was incubated with or without nucleotides (1 mM),
heparin (10 μg/mL), and/or protamine (20 μg/mL) at
37°C for 15 min. 1 mM bis(sulphosuccinimidyl)suberate
(BS
3) was added and the reactions were incubated for
additional 1 h at 20°C. Reactions were stopped by add-
ing SDS-loading dye and subsequent heating at 95°C for
5 min. Proteins were separated by SDS-PAGE and visua-
lized by silver staining.
Degradation of FGF2 and FGF2(K134A) by NE
Degradation of FGF2 and FGF2(K134A) by NE was per-
formed as described previously [12]. FGF2 (with his-tag)
and FGF2(K134A) (with his-tag) were expressed and
purified as described previously [13].
Elisa
FGF2-ELISA was performed according to the supplier’s
instructions (Ray Biotech, GA, USA). In brief, 100 μLo f
each sample containing FGF2 were added to a 96-well
plate, coated with antibody specific for human FGF2,
and incubated at 4°C over night. Wells were washed 4
times and then incubated with biotinylated anti-human
FGF2 antibody for 1 h at RT. After additional washing
(4 times) streptavidin solution was added to each well
and incubated for 45 min. After washing (4 times)
3,3’,5,5’-tetramethylbenzidine-solution was added to the
wells and incubated for 30 min, the reactions were
stopped and the absorbance was read at 450 nm
immediately.
Measurement of ATP content
ATP concentration was determined luminometrically as
described previously [7].
Results
Dissociation constant of ATP-binding to FGF2
Previous work has shown that ATP can bind to FGF2
[9,14]. To characterize this binding of ATP to FGF2 in
more detail, we used equilibrium microdialysis to
directly examine the ATP-binding properties of the
growth factor. Equilibrium microdialysis was performed
with 10 μM FGF2 in the reaction chamber. As ATP
concentrations increased from 1 to 80 μM, the amount
of ATP bound to FGF2 increased as well reaching a
maximum level and indicating a saturation binding
behavior (Figure 1A). Consistent with the radiolabeling
experiments [9] and MALDI-TOF data [14,15], FGF2 (10
μM) clearly bound ATP at concentrations between 1 and
80 μM. ATP binding data were replotted in a Scatchard
plot and the binding constant was calculated. The linear
Scatchard plot gave a value of 1.2 for the number of inde-
pendent binding sites, indicating that one molecule ATP
binds to one molecule FGF2 (Figure 1B). The calculated
dissociation constant (KD) is 59.8 μM.
Conformational change of secondary structure of FGF2
after ATP-binding
We collected CD spectra of untreated FGF2 only and
FGF2 preincubated with nucleotides to investigate puta-
tive conformational changes of the secondary structure
of the FGF2/ligand-complex. The CD-spectrum of FGF2
(concentration: 25 μM) showed a curve progression char-
acteristic for a protein rich in b-structure (Figure 1C).
The signal decreased from 230 nm onward reaching a
broad minimum around 205 nm to increase again to the
base level, as it has been reported previously for NGF [7].
In contrast to untreated FGF2, FGF2 incubated with ATP
(100 μM) showed a clear decrease of the amplitude of the
broad minimum (Figure 1C) and no increase afterwards
to the base level at 195 nm. This indicates a decrease of
percentage of b-structure and finally a conformational
change of FGF2 after interaction with this nucleotide. In
contrast, the CD-spectrum of FGF2 did not significantly
change after addition of AMP (100 μM). After addition
of ADP (100 μM) the CD-spectrum changed only moder-
ately compared to untreated FGF2.
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Previous studies reported dimerization of FGF2 and
additional receptor binding induced by heparin [16].
Thus, we were highly interested in finding out whether
ATP binding or subsequent structural changes could
also promote FGF2 dimerization. Addition of 1 mM
ATP and BS
3 (Figure 2A, lane 5) did not induce
dimerization whereas addition of heparin and BS
3 did
(Figure 2A, lane 3). However, co-incubation of FGF2
with heparin (10 μg/mL), ATP (1 mM) and BS
3 (Figure
2A, lane 6) did promote formation of dimers with a
similar dimer/monomer ratio as observed for incuba-
tion with heparin and subsequently BS
3-crosslinking
only (Figure 2A, lane 3).
Stability of FGF2 and FGF2 (K134A) against proteolytic
digestion
Recently, we reported that a variant form of FGF2 (FGF2-
Quadro, [12]) with mutations in the heparin binding
domain did not show enhanced stability against trypsin
degradation after incubation with ATP because of its
reduced ATP-binding capacity. Here, we investigated the
stability of mutant FGF2(K134A) against degradation by
neutrophil elastase (NE). The K134A variant showed a
partial stability against degradation by NE independent
of this protein being preincubated with ATP or not
(Figure 2B). Addition of ATP did not additionally protect
FGF2(K134A) from protease digestion as revealed by
silver staining. Interestingly, the ATP-binding capacity of
FGF2(K134A) was only moderately reduced compared to
the wild-type [9].
Stability of FGF2 in aqueous solution is increased after
ATP-binding
ATP-binding to FGF2 increased the stability of this
growth factor against proteolytic degradation as
described previously [12]. Here, we wanted to investigate
whether ATP protects the growth factor also from phy-
sical inactivation, meaning the stability in aqueous solu-
tion. Therefore, we performed stability experiments of
FGF2 in Tris-buffered aqueous solution at 37°C and
subsequently determined FGF2-concentration by ELISA.
We incubated untreated FGF2, preincubated with ATP
(200 μM) or preincubated with heparin (10 μg/mL) at
37°C for 2 h. Figure 3 shows that the concentration of
unprotected FGF2 decreased drastically already after
10 minutes of incubation from 5 ng/mL to about
0.5 ng/mL, whereas the concentration of FGF2, preincu-
bated with heparin, only marginally decreased over the
period of 2 h from about 5 ng/mL to about 4 ng/mL.
The stability of FGF2, preincubated with ATP, decreased
from about 5 ng/mL to about 3 ng/mL after 30 min and
to about 2 ng/mL after 120 min.
Additionally, we measured the ATP concentration
luminometrically at different points of time in the
experiment with FGF2 preincubated with ATP. The
ATP-concentration did not change significantly indicat-
ing that ATP was stable over the observed period of two
hours (data not shown).
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Figure 1 Binding of ATP to FGF2 and nucleotide-induced
conformational change. (A) The binding of ATP to FGF2 was
determined by equilibrium microdialysis. FGF2 (10 μM) was
incubated with different concentrations of ATP in rapid equilibrium
dialysis inserts in a Teflon Base Plate for 16 h at 20°C. ATP in the
dialysis chambers was determined using ATP Kit SL and a LKB
Wallac luminometer. (B) The data were analyzed in a Scatchard plot
using a calculated amount of bound and free ATP to determine KD
of FGF2/ATP-complex. The equation was used to calculate the
number of binding sites of 1.2 (y-value is set = 0) and the KD value
of 59.8 μM (the reciprocal of the negative gradient). (C) CD spectra
of FGF2 (25 μM) measured in Tris-HCl (pH 7.5). Effects of different
nucleotides (100 μM, respectively) are shown. The ordinate axis
presents the molecular ellipticity.
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residues of used stabilizers
In order to investigate the importance of the number
and the position of phosphate residues of putative
FGF2-stabilizers, we protected FGF2 from trypsin degra-
dation using substances with a different number of
phosphate residues in the range of 2 (pyrophosphate) to
6 (inositol hexaphosphate). FGF2 was preincubated with
each substance to form FGF2/ligand complexes. Then,
trypsin was added and the samples were incubated for
3 h. It was generally observed that with an increasing
number of phosphate residues the protective effect on
FGF2 against tryptic degradation increased respectively
(Figure 4). Inositol hexaphosphate (6 phosphate resi-
dues) revealed a strong protection of the growth factor
from tryptic digestion, whereas ATP and tripolypho-
sphate (3 phosphate residues) showed a slightly
decreased protective effect. Pyrophosphate (2 phosphate
residues) only had a marginal protective effect on FGF2
degradation under these experimental conditions.
Discussion and conclusions
Besides the large groups of ATP-binding proteins, for
example the kinases and the ATPases with more or less
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Figure 2 FGF2 monomers and dimers after cross-linking and variant forms of FGF2 after proteolytic degradation. (A) FGF2 (1.5 μg) in
Tris-HCl (pH 7.5) was incubated with 1 mM ATP and 10 μg/mL heparin and 20 μg/mL protamine at 37°C. After 15 min, 1 mM BS
3-crosslinker
was added and the samples were incubated for 1 h at 20°C. Reactions were stopped by addition of SDS-loading dye and boiling. The proteins
were separated by 15% SDS-PAGE and visualized by silver staining. (B) Two μg FGF2 (K134A) in Tris-HCl (pH 7.5), were incubated with ATP (100
μM) or without ATP at 37°C. After 15 min FGF2 and FGF2 (K134A) were incubated with 200 ng NE at 37°C for 2 h. The reactions were stopped
by addition of SDS-loading dye and boiling. The samples were separated by SDS-PAGE and protein was visualized by silver staining.
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Kinase 2), some other ATP-binding proteins are
described in the literature, e.g. ABC transporters, metal-
lothionein, chaperons and actins which lack such a
domain [17]. Growth factors have been identified as
ATP-binding proteins only recently [6]. Nerve growth
factor (NGF), brain-derived growth factor (BDNF), vas-
cular endothelial growth factor (VEGF; personal com-
munication R. Gast) and FGF2 are associated with ATP
which is very likely to be important for their biological
activity.
In this work, the binding affinity of ATP to FGF2 was
determined by equilibrium microdialysis. The KD value
of 59.8 μMs h o w e do n l ym o d e r a t eb i n d i n go fA T Pt o
FGF2 which is contradictory to the binding affinities
described for most kinases/ATP- and ATPases/ATP-
complexes. This moderate binding constant is well
observed to be not consistent with the ATP-concentra-
tion in the low nmolar range necessary for neuroprotec-
tive activity of FGF2 in cell culture experiments
demonstrated recently [8]. Based on the experiments
described in this paper, a high affine binding domain of
ATP besides the 59.8 μmolar binding domain is very
likely to be present. However, the KD values of other
ATP-binding proteins, e.g. gelsolin (KD 32 μM, [18]), p-
glycoprotein (KD 200 μM; [19]) and metallothionein (KD
176 μM; [20]), were in a similar range like FGF2. The
value of 1.2 for the number of independent ATP-bind-
ing sites of FGF2 showed that one molecule of FGF2
binds one molecule of ATP. This is in line with
MALDI-TOF experiments where binding of one mole-
cule of ATP to one molecule of FGF2 was demonstrated
[14,15]. Only in the presence of magnesium two mole-
cules of ATP were able to bind to FGF2. Comparing the
KD value of FGF2/ATP (KD:6 0μM) with FGF2/HSPGs
(KD: 1-50 nM, [21,22]) demonstrated that the binding of
HSPGs to FGF2 was preferred.
Although the dissociation constant of ATP-binding to
FGF2 was rather high, this binding leads to a significant
change in the secondary structure of FGF2 as demon-
strated by CD-spectroscopy (Figure 1C). Thereby the
amplitude of structural change depends on the number
of phosphate residues of the nucleotides (ATP > ADP >
AMP). Interestingly, the conformational change after
ATP-binding to FGF2 was more distinct than that of
heparin [23,24] and may explain the physiological
importance for neuroprotective activity of FGF2 [8].
It has been known for many years that binding of
heparin or HSPGs to FGF2 forces the dimerization of the
growth factor and that this is important for interaction
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Figure 4 Stability of FGF2 depends on the number of phosphate residues of bound stabilizers.F G F 2( 5μM) was preincubated with
different stabilizers (100 μM each) at 37°C for 15 min. The complexes were then treated with trypsin (50 ng) at 37°C for 3 h. The samples were
separated by SDS-PAGE and protein was visualized by Coomassie-staining.
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Figure 3 Stability of FGF2 in aqueous solution. FGF2 (5 ng/mL)
was incubated in 25 mM Tris, HCl (pH 7.5) at 37°C with or without
preincubation with ATP (200 μM) or heparin (10 μg/mL),
respectively. Samples were collected at different points of time and
FGF2-concentration was determined with Human bFGF ELISA Kit
(RayBiotech, USA) in triplicate.
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Page 5 of 7with its specific receptors ([16]; Figure 2A). In contrast to
heparin, ATP did not lead to a dimerization of FGF2 as
observed in cross-linking experiments (Figure 2A,
lane 5). It could be speculated that ATP is not involved
in receptor activation by dimerization. More important
seems to be the protective effect of this abundantly pre-
sent nucleotide on FGF2. This is in line with recent data
showing that the main role of heparin or HSPGs in
FGF1-induced signaling is to protect this naturally
unstable protein from heat and proteolytic degradation
[25].
The ATP binding capacity of the mutant FGF2
(K134A) is reduced by about 20% compared to wt-FGF2
[9]. Adding ATP to FGF2 (K134A) did not show addi-
tional protective effects against degradation by NE
(Figure 2B). Furthermore, mutant FGF2 (K134A) did
not show neuroprotective activity [13]. It could be
speculated that the not observed protectivity of ATP on
FGF2 (K134A) is important for the loss of neuroprotec-
tivity of this variant form of the growth factor [8].
Besides the protection of FGF2 by bound ATP from
proteolytic digestion [12],w ed e m o n s t r a t e di nt h i s
work that ATP additionally protects FGF2 from physi-
cal degradation. It is known that FGF2 is rapidly
degraded when incubated in aqueous solution without
stabilizers [26]. This is the main problem in the use of
this important growth factor for medical applications.
Observing the stability of FGF2 in buffered aqueous
solution over a period of 2 hours clearly showed a
protective effect of ATP bound to FGF2 (Figure 3).
However, this protective effect was not as strong as
observed with heparin; heparin protected FGF2 nearly
completely from physical degradation (Figure 3). This
decreased effect on the stability of FGF2 by ATP
compared to heparin might be explained by the higher
dissociation constant of ATP (59.8 μM) in contrast to
heparin (1-50 nM).
The CD-data clearly demonstrate that the number of
phosphate residues of the nucleotide (AMP, ADP, and
ATP) is very important for the conformational change
o ft h eg r o w t hf a c t o r .T h e r e f o r ew ei n v e s t i g a t e dt h e
effect of FGF2-stabilization by different ligands exhibit-
ing phosphate residues in the range of 2-6 (Figure 4).
The results show that the number of negatively
charged groups is important for the protective effect
against proteolysis. However, thereby it was not taken
into account that each substance has a different struc-
ture with different distances between the phosphate
residues.
Taken together our results indicate that the binding
affinity of ATP to FGF2 is moderate, but has a high
impact on the secondary structure of the protein. This
change in secondary structure might be the reason for
the observed effect of ATP on the FGF2-stability, which
could be classified between non-protected-FGF2 and a
full-protection by FGF2/heparin-complex. Interestingly,
the protective effect of ATP (0.1 mM) on FGF2 could
also be detected after addition of 0.1 mM MgCl2 leading
to the formation of the physiologically important ATP/
Mg
2+-complex (Figure 5). Such a ATP/Mg
2+-complex
(molar ratio 1:1) is the predominant form of extracellu-
lar ATP in tissue.
Taken together, a putative physiological role of FGF2-
protection by ATP in cell culture and tissue is well con-
ceivable and has to be proved in future studies.
Abbreviations
FGF2: fibroblast growth factor 2; NGF: nerve growth factor; BDNF: brain-
derived growth factor; VEGF: vascular endothelial growth factor; NE:
neutrophil elastase.
Acknowledgements
We thank Prof. H.U. Humpf for support with circular dichroism spectroscopy.
We acknowledge support by Deutsche Forschungsgemeinschaft and Open
Access Publication Fund of University of Muenster.
Authors’ contributions
KR carried out all experiments and drafted the manuscript.
Received: 19 October 2010 Accepted: 29 March 2011
Published: 29 March 2011
References
1. Saraste M, Sibbald PR, Wittinghofer A: The p-loop- a common motif in
ATP- and GTP-binding proteins. Trends Biochem Sci 1990, 15:430-440.
2. Traut TW: The functions and consensus motifs of nine types of peptide
segments that form different types of nucleotide-binding sites. Eur J
Biochem 1994, 222:9-19.
3. Semenov DV, Kanyshkova TG, Buneva VN, Nevinsky GA: Human milk
lactoferrin binds ATP and dissociates into monomers. Biochem Mol Biol
Int 1999, 47:177-184.
4. Takeda S, Miyauchi S, Nakayama H, Kamo N: Adenosine 5’-triphosphate
binding to bovine serum albumine. Biophys Chem 1997, 69:175-183.
5. Kambe H, Ito H, Kimura Y, Okochi T, Yamamoto H, Hashimoto T, Tagawa K:
Human plasma gelsolin reversible binds Mg-ATP in Ca
2+-sensitiv
manner. J Biochem 1992, 111:722-725.
6. Klumpp S, Kriha D, Bechmann G, Maassen A, Maier S, Pallast S, Hoell P,
Krieglstein J: Phosphorylation of the growth factors bFGF, NGF and
Figure 5 Stabilization of FGF2 by ATP/Mg
2+-complex.F G F 2
(5 μM) in Tris-HCl (pH 7.5) was incubated with or without ATP (100
μM), MgCl2 (100 μM) and trypsin (50 ng) at 37°C for 3 h. The
samples were separated by SDS-PAGE and protein was visualized by
silver-staining.
Rose BMC Biochemistry 2011, 12:14
http://www.biomedcentral.com/1471-2091/12/14
Page 6 of 7BDNF: a prerequisite for their biological activity. Neurochem Int 2006,
48:131-137.
7. Hasche A, Ferenz KB, Rose K, König S, Humpf HU, Klumpp S, Krieglstein J:
Binding of ATP to nerve growth factor: Characterization and relevance
for bioactivity. Neurochem Int 2010, 56:276-284.
8. Rose K, Litterscheid S, Klumpp S, Krieglstein J: Fibroblast growth factor 2
requires complex formation with ATP for neuroprotective activity.
Neuroscience 2009, 164:1695-700.
9. Rose K, Pallast S, Klumpp S, Krieglstein J: ATP-binding on fibroblast growth
factor 2 partially overlaps with the heparin binding domain. J Biochem
2008, 144:343-347.
10. Thompson LD, Pantoliano MW, Springer BA: Energetic characterization of
the basic fibroblast growth factor-heparin interaction: identification of
the heparin binding domain. Biochemistry 1994, 33:3831-3840.
11. Sakiyama-Elbert SE, Hubbell JA: Controlled release of nerve growth factor
from a heparin-containing fibrin-based cell ingrowth matrix. J Control
Release 2000, 69:149-58.
12. Rose K, Gast RE, Seeger A, Krieglstein J, Klumpp S: ATP-dependent
stabilization and protection of fibroblast growth factor 2. J Biotechnol
2010, 145:54-59.
13. Rose K, Kriha D, Pallast S, Junker V, Klumpp S, Krieglstein J: Basic fibroblast
growth factor: Lysine 134 is essential for its neuroprotective activity.
Neurochem Int 2007, 51:25-31.
14. König S, Hasche A, Pallast S, Krieglstein J, Klumpp S: Detection of ATP-
binding to growth factors. J Am Soc Mass Spectrom 2008, 19:91-95.
15. Klumpp S, König S, Hasche A, Pallast S, Rose K, Krieglstein J: Binding of ATP
to growth factors is a prerequisite of their neuroprotective activity.
J Neurochem 2007, 102(supplement 1):125.
16. Schlessinger J, Plotnikov AN, Ibrahimi OA, Eliseenkova AV, Yeh BK, Yayon A,
Linhardt RJ, Mohammadi M: Crystal structure of a ternary FGF-FGFR-
heparin complex reveals a dual role for heparin in FGFR binding and
dimerization. Mol Cell 2000, 6:743-750.
17. Venglarik CJ, Schultz BD, Frizzell RA, Bridges RJ: ATP alters current
fluctuations of cystic fibrosis transmembrane conductance regulator:
evidence for a three-state activation mechanism. J Gen Physiol 1994,
104:123-146.
18. Urosev D, Ma Q, Tan AC, Robinson RC, Burtnick LD: The structure of
gelsolin bound to ATP. J Mol Biol 2006, 257:765-772.
19. Romsicki Y, Sharom FJ: The ATPase and ATP-binding functions of
P-glycoprotein. Eur J Biochem 1998, 256:170-178.
20. Jiang L, Maret W, Vallee BL: The ATP-metallothionein complex. Proc Natl
Acad Sci USA 1998, 95:9146-9149.
21. Nugent MA, Edelman ER: Kinetics of basic fibroblast growth factorbinding
to its receptor and heparan sulfate proteoglycan: a mechanism for
cooperactivity. Biochemistry 1992, 22:8876-8883.
22. Chen HL, Gallagher JT, Rudland PS, Fernig DG: Interaction of Heparan
Sulfate from Mammary Cells with Acidic Fibroblast Growth Factor (FGF)
and Basic FGF. Biol Chem 1998, 273:7303-7310.
23. Bittoun P, Bagheri-Yarmand R, Chaubet F, Crepin M, Jozefonvicz J,
Fermandjian : Effects of the binding of a dextran derivative on fibroblast
growth factor 2: secondary structure and receptor-binding studies.
Biochem Pharmacol 1999, 57:1399-1406.
24. Moy FJ, Safran M, Kitchen D, Bohlen P, Aviezer D, Yayon A, Powers R:
Properly oriented heparin-decasaccharide-induced dimers are the
biologically active form of basic fibroblast growth factor. Biochemistry
1997, 36:4782-4791.
25. Zakrzewska M, Wiedlocha A, Szlachcic A, Krowarsch D, Otlewski J, Olsnes S:
Increased protein stability of FGF1 can compensate for its reduced
affinity for heparin. J Biol Chem 2009, 284:25388-25403.
26. Mi FL, Shyu SS, Peng CK, Wu YB, Sung HW, Wang PS, Huang CC:
Fabrication of chondroitin sulphate-chitosan composite artificial
extracellular matrix for stabilization of fibroblast growth factor. J Biomed
Mater Res A 2005, 76:1-15.
doi:10.1186/1471-2091-12-14
Cite this article as: Rose: Interaction of ATP with fibroblast growth
factor 2: biochemical characterization and consequence for growth
factor stability. BMC Biochemistry 2011 12:14.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Rose BMC Biochemistry 2011, 12:14
http://www.biomedcentral.com/1471-2091/12/14
Page 7 of 7